Fatigue Improvement after Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Apropos of a CaseJavier Munoz* and Philip Kuriakose
Department of Hematology and Oncology, Henry Ford Hospital, 2799 W, Grand Blvd, Detroit Michigan 48202, USA
- Corresponding Author:
- Javier Munoz
Department of Hematology and Oncology
Henry Ford Hospital, Hematology-Oncology
2799 West Grand Blvd, Detroit, MI 48202, USA
Tel: 713-792-3934 / 713-854-6211
Received Date: May 02, 2012; Accepted Date: June 14, 2012; Published Date: June 18, 2012
Citation:Munoz J, Kuriakose P (2012) Fatigue Improvement after Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Apropos of a Case. J Palliative Care Med 2:118. doi:10.4172/2165-7386.1000118
Copyright: © 2012 Munoz J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A 54-year-old male presented with shortness of breath and was diagnosed with pulmonary emboli. Laboratory studies revealed hemolytic anemia. Flow cytometry showed a prominent white blood cell clone without CD59 in 85% (NV 0-3.0) and red blood cells with 8.5% CD59 absence (NV 0-3.0) confirming a diagnosis of paroxysmal nocturnal hemoglobinuria. Eculizumab was started to decrease the possibility of a thrombotic recurrence, with incidentally, a marked subjective improvement of symptomatology, as fatigue, was seen. We reviewed current literature regarding the improvement in fatigue seen in patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab.